1. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas;Bautista;Pediatr Blood Cancer,2014
2. Melanoma and melanocytic tumors of uncertain malignant potential in children, adolescents and young adults – the Stanford experience 1995–2008;Berk;Pediatr Dermatol,2010
3. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations;Buczkowicz;Nat Genet,2014
4. Three decades of chemotherapy for childhood cancer – from cure “at any cost” to cure “at least cost”;Craft;Cancer Surv,1990
5. EMA. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004 (Official Journal L 378, 27/12/2006 p.1–19). Available at: http://ec.europa.eu/health/documents/eudralex/vol-1/index_en.htm.